Welcome to our dedicated page for Cross Ctry Healthcare SEC filings (Ticker: CCRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cross Country Healthcare filings document the regulatory record for a Nasdaq-listed healthcare workforce solutions company with common stock registered under CCRN. Its SEC reports include Form 8-K disclosures for operating and financial results, Regulation FD communications, material agreements, executive appointments and departures, compensation arrangements and other governance matters.
Proxy and shareholder materials describe director elections, voting matters, executive compensation, board governance and capital-structure information. The filing record also covers the company’s staffing, recruitment, advisory and Intellify platform activities through business updates and financial disclosures tied to healthcare labor markets and technology-enabled workforce management.
Cross Country Healthcare’s General Counsel and Secretary, Susan E. Ball, reported an amended insider transaction reflecting tax withholding tied to restricted stock vesting. On March 31, 2025, multiple entries show shares of common stock withheld to cover tax obligations, including transactions of 1,740, 1,689, 2,015 and 3,942 shares at a price of $14.89 per share. These were coded as “F,” indicating shares withheld by the issuer rather than open-market sales. After these transactions, she directly beneficially owned 176,032 shares of Cross Country Healthcare common stock. The amendment corrects the transaction date originally reported as April 2, 2025, confirming that the activity occurred on March 31, 2025.
Cross Country Healthcare Inc. reported that its Chief Accounting Officer received a grant of 12,311 restricted shares of common stock on December 18, 2025. These shares were granted at a price of $0 and increase the officer’s directly owned common stock to 31,110 shares after the transaction.
The restricted stock award will vest in three substantially equal installments on December 18, 2026, March 31, 2027, and March 31, 2028. The Compensation Committee approved the number of restricted shares to be granted on December 18, 2025, following the termination of a Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025. After the first vesting date 12 months from grant, the remaining installments will vest on March 31 of the next two years to align with prior awards.
Cross Country Healthcare, Inc. reported that director Kevin C. Clark received a grant of 162,672 restricted shares of common stock on December 18, 2025 at a price of $0. These restricted stock awards vest in three substantially equal installments on December 18, 2026, March 31, 2027, and March 31, 2028, with later vesting dates aligned to the company’s existing restricted stock schedule.
The grant amount was approved on December 18, 2025 following the termination of a Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025. After this award, Mr. Clark beneficially owns 809,170 shares directly and 3,961 shares indirectly through his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Cross Country Healthcare, Inc. reported that its General Counsel and Secretary, Susan E. Ball, received a grant of 35,804 restricted shares of common stock on December 18, 2025 at a stated price of $0. Following this grant, she beneficially owns 211,836 shares directly.
The restricted shares vest in three substantially equal installments on December 18, 2026, March 31, 2027 and March 31, 2028. The Compensation Committee approved the number of restricted shares to be granted on December 18, 2025 instead of March 31, 2025, after the termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc. and Aya Healthcare, Inc. on December 3, 2025.
Cross Country Healthcare announced a major leadership change as President and Chief Executive Officer John A. Martins separated from the company effective December 14, 2025, and stepped down from the board, which was reduced from seven to six members. The board appointed current chairman, former CEO, and co‑founder Kevin C. Clark as President and CEO, effective the same date, and he will continue to serve as chairman.
Under his employment agreement, Martins will receive cash severance equal to two years of his base salary of $875,000 plus two times his average actual bonus over the prior three years, paid over 24 months, along with up to 24 months of continued benefits if elected. All of his unvested equity awards will fully vest, with outstanding performance share awards vesting at target. The company plans to finalize an employment agreement setting Clark’s compensation and intends to file an amendment when those terms are determined.
Cross Country Healthcare (CCRN) filed its Q3 2025 10‑Q, reporting revenue of $250,052 thousand and a net loss of $4,774 thousand, or $0.15 per diluted share. For the nine months, revenue was $817,532 thousand with a net loss of $11,923 thousand.
Results reflected softer volumes and several non-core charges. The quarter included $4,147 thousand of Aya Merger-related fees, $1,530 thousand of restructuring costs, and $1,102 thousand of legal and other losses. Operating loss was $5,973 thousand. Nurse and Allied Staffing generated $201,950 thousand of revenue; Physician Staffing contributed $48,102 thousand.
Liquidity remained solid: cash and cash equivalents were $99,132 thousand with no debt outstanding. The asset‑based revolver had $121.4 million of borrowing base availability, or $103.0 million net of $18.4 million in letters of credit. Operating cash flow was $30,012 thousand year‑to‑date. The pending Aya Merger remains subject to FTC review under the HSR Act; the HSR waiting period extends during the government shutdown, and the parties are discussing an end‑date extension.
Cross Country Healthcare (CCRN) set its 2025 Annual Meeting for December 9, 2025 at 12:00 p.m. ET, to be held virtually at www.virtualshareholdermeeting.com/CCRN2025. Stockholders of record as of October 14, 2025 may vote.
The agenda includes three items: elect seven director nominees for one-year terms; ratify Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2025; and approve, on a non-binding advisory basis, 2024 executive compensation.
The company notes its proposed merger with Aya Healthcare, Inc. is expected to close in the fourth quarter of 2025; the Annual Meeting will not be held if the merger closes before December 9.
Governance highlights include a seven-member Board with a Lead Independent Director and fully independent Audit, Compensation, and Governance & Nominating Committees. 2024 results cited include revenue above $1.3 billion, Adjusted EBITDA of $49.1 million (3.7% margin), Adjusted EPS of $0.46, strong cash flow of $120.1 million, repurchases of 2.4 million shares for $36.8 million, and no outstanding long-term debt.
On September 25, 2025 Cross Country Healthcare, Inc. announced its Board set the 2025 virtual-only Annual Meeting for December 9, 2025, which is more than 30 days after last year’s meeting. The meeting will only occur if the pending merger with Aya Healthcare, Inc. (the Aya Merger) is not completed beforehand; the company continues to expect the Aya Merger to close in the fourth quarter of 2025. If the merger is completed first, Cross Country will become a wholly owned subsidiary of Aya and the Annual Meeting will not be held. The company set a deadline of October 10, 2025 for stockholder proposals, nominations and Rule 14a-19 universal proxy notices, and said the proxy statement will be made available by or prior to October 30, 2025.
Cross Country Healthcare, Inc. disclosed that under its Merger Agreement with Aya Holdings II Inc., the contractual “End Date” for completing their planned merger was automatically extended from September 3, 2025 to December 3, 2025. All other terms of the Merger Agreement remain unchanged.
The company and Aya have each certified to the U.S. Federal Trade Commission that they have substantially complied with the agency’s “Second Request” for additional information related to the transaction. Subject to customary closing conditions and required regulatory approvals, the merger is now expected to close in the fourth quarter of 2025.